M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer
Status:
Recruiting
Trial end date:
2021-10-31
Target enrollment:
Participant gender:
Summary
This phase Ib trial studies the best dose and side effects of eribulin mesylate when given
together with M7824)in treating patients with triple negative breast cancer that has spread
to other places in the body. Drugs used in chemotherapy, such as eribulin mesylate, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal
antibodies, such as M7824, may help the body's immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread. Giving eribulin mesylate and
M7824 may work better at treating triple negative breast cancer.